• Babany, G., V. Descatoire, M. Corbic, et al.: Regulation of renal cytochrome P-450. Effects of two-thirds hepatectomy, cholestasis, biliary cirrhosis and post-necrotic cirrhosis on hepatic and renal microsomal enzymes. Biochem. Pharmacol. 1985, 34, 311320.
  • Butner, J. T. M., T. Zysset & J. Reichen: Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vino and microsomal membrane lipid composition. Biochem. Pharmacol. 1993, 46, 983991.
  • Chen, J., M. Murray, C. Liddle, X.-M. Jiang & G. C. Farrell: Downregulation of male-specific cytochrome P450s 2C11 and 3A2 in bile duct-ligated male rats: importance to reduced hepatic content of cytochrome P450 in cholestasis. Hepatology 1995, 22, 580587.
  • Cribb, A. E., S. P. Spielberg & G. P. Griffin: N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drag Metab. Dispos. 1995, 23, 406414.
  • George, J., M. Murray, K. Byth & G. C. Farrell: Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995, 21, 120128.
  • Guengerich, F. P.: Human cytochrome P-450 enzymes. Life Sci. 1992, 50, 14711478.
  • Hutterer, F., H. Denk, P. G. Bacchin, et al.: Mechanism of cholestasis. 1. Effect of bile acids on microsomal cytochrome P450 dependent biotransformation system in vitro. Life Sci. 1970, 9, 877887.
  • Ioannides, C.: Cytochromes P450: metabolic and toxicological aspects. Boca Raton, CRC Press Inc., 1996.
  • Ishak, K. G. & R. S. Markin: Liver. In: Anderson's Pathology. 10th ed. Eds.: I.Damjanov & J.Linder. St. Louis, Mosby-Year Book, Inc., 1996, pp. 17791858.
  • Kountouras, J., B. H. Billing & P. J. Scheuer: Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Brit. J. Exp. Path. 1984, 65, 305311.
  • Lowry, O. H., N. J., Rosebrough, A. L., Farr, et al.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265275.
  • McLean, A. J. & D. J. Morgan: Clinical pharmacokinetics in patients with liver disease. Clin. Pharmacokin. 1991, 21, 4269.
  • Mourelle, M., J. L. Amezcua & L. Favari: Heterogeneity of changed on the disposition of aspirin in rats with CCl4-induced chronic liver damage. Biochem. Pharmacol. 1987, 36, 30213025.
  • Murray, M., L. Zaluzny & G. C. Farrell: Drug metabolism in cirrhosis. Selective changes in cytochrome P-450 isozymes in the choline-dcficient rat model. Biochem. Pharmacol. 1986, 35, 18171824.
  • Murray, M., L. Zaluzny & G. C. Farrell: Impaired androgen 16α-hydroxylation in hepatic microsomes from carbon tetrachloridecirrhotic male rats. Gastroenterology 1987, 93, 141147.
  • Niwa, T., H. Kancko, Y. Naritomi, et al.: Species and sex differences of testosterone and nifedipine oxidation in liver microsomes of rat. dog and monkey. Xenobiotics 1995, 25, 10411049.
  • Omura, T. & R. Sato: The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem. 1964, 239, 23702378.
  • Paolini, M., R. Mesirca, L. Pozzetti et al.: Molecular non-genetic biomarkers related to fenarimol cocaricinogenesis: organ- and sex-specific CYP induction in rat. Cancer Letters 1996, 101, 171178.
  • Peter, P., R. Böcker, P. H. Beaune, et al.: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 1990, 3, 566573.